Sanofi (SNY) Non-Current Debt (2009 - 2025)

Sanofi has disclosed Non-Current Debt across 17 years of filings, most recently posting $16.6 billion for Q4 2025.

• Non-Current Debt for Q4 2025 came in at $16.6 billion, up 31.63% year-over-year; the trailing twelve-month figure through Dec 2025 was $16.6 billion (up 31.63% YoY), and the FY2025 annual result was $16.6 billion, up 31.63% from the prior year.
• Non-Current Debt came in at $16.6 billion for Q4 2025 at Sanofi, up from $14.9 billion in the prior quarter.
• In the past five years, Non-Current Debt ranged from a high of $21.6 billion in Q2 2021 to a low of $12.6 billion in Q4 2024.
• The 5-year median for Non-Current Debt is $15.5 billion (2023), against an average of $16.2 billion.
• Across the five-year window, Non-Current Debt declined 22.62% in 2022 and jumped 31.63% in 2025, its largest moves.
• Sanofi's Non-Current Debt stood at $19.6 billion in 2021, then slipped by 22.62% to $15.2 billion in 2022, then gained by 1.84% to $15.4 billion in 2023, then dropped by 18.38% to $12.6 billion in 2024, then surged by 31.63% to $16.6 billion in 2025.
• The last three Non-Current Debt figures came in at $16.6 billion (Q4 2025), $14.9 billion (Q2 2025), and $12.6 billion (Q4 2024), per Business Quant data.